REVELATION BIOSCIENCES, INC. 8-K

What Happened Revelation Biosciences, Inc. (REVB) announced its financial results for the three and twelve months ended December 31, 2025 in a press release issued February 26, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K (Item 2.02: Results of Operations and Financial Condition). The Form 8-K was signed by Chief Financial Officer Chester S. Zygmont, III.

Key Details

• Press release dated February 26, 2026 announcing results for the three and twelve months ended December 31, 2025.
• The press release is furnished as Exhibit 99.1 to the Form 8-K (Item 9.01(d)).
• The Form 8-K covers Item 2.02 (results of operations and financial condition).
• The filing was executed and dated February 26, 2026 by CFO Chester S. Zygmont, III.

Why It Matters This 8-K signals that Revelation has released its most recent quarterly and full-year financial results — information investors use to assess recent earnings, revenue, cash position and trends. The Form 8-K itself does not include the numeric results; investors should read the attached Exhibit 99.1 press release (or the company’s full earnings release/SEC filings) to see specific figures and any commentary on performance or outlook.